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Abstract
Objective To compare the gene expression patterns of synovial cells from
inflamed or normal/reactive areas of synovial membrane obtained from the
same patient with osteoarthritis (OA). Methods At the time of total knee
replacement, synovial tissues were obtained from 12 patients with knee OA.
The inflammation status of the synovial membrane was characterized according
to macroscopic criteria and classified as normal/reactive or inflamed. Biopsy
samples were cultured separately for 7 days. Microarray gene expression
profiling was performed on normal/reactive and inflamed areas. Western blot
and immunohistochemistry were used to confirm the identified genes that were
differentially expressed. Results We identified 896 genes that were differentially
expressed between normal/reactive and inflamed areas. The key pathways were
related to inflammation, cartilage metabolism, Wnt signaling, and angiogenesis.
In the inflammation network, the genes TREM1 and S100A9 were strongly up-
regulated. T...
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Gene Expression Pattern of Cells From Inflamed and
Normal Areas of Osteoarthritis Synovial Membrane
Ce´cile Lambert,1 Jean-Emile Dubuc,2 Eula`lia Montell,3
Josep Verge´s,3 Carine Munaut,4 Agne`s Noe¨l,4 and Yves Henrotin1
Objective. To compare the gene expression pat-
terns of synovial cells from inflamed or normal/reactive
areas of synovial membrane obtained from the same
patient with osteoarthritis (OA).
Methods. At the time of total knee replacement,
synovial tissues were obtained from 12 patients with
knee OA. The inflammation status of the synovial
membrane was characterized according to macroscopic
criteria and classified as normal/reactive or inflamed.
Biopsy samples were cultured separately for 7 days.
Microarray gene expression profiling was performed on
normal/reactive and inflamed areas. Western blot and
immunohistochemistry were used to confirm the identi-
fied genes that were differentially expressed.
Results. We identified 896 genes that were differ-
entially expressed between normal/reactive and in-
flamed areas. The key pathways were related to inflam-
mation, cartilage metabolism, Wnt signaling, and
angiogenesis. In the inflammation network, the genes
TREM1 and S100A9 were strongly up-regulated. The
genes MMP3, MMP9, CTSH (cathepsin H), and CTSS
(cathepsin S) were significantly up-regulated in the
cartilage catabolism pathway, while the most up-
regulated anabolism enzyme gene was HAS1. In the Wnt
signaling pathway, the genes for Wnt-5a and low-density
lipoprotein receptor–related protein 5 were up-
regulated, while the gene FZD2 and the gene for Dkk-3
were down-regulated. Finally, STC1, which codes for a
protein involved in angiogenesis, was identified as the
most up-regulated gene in inflamed compared with
normal/reactive areas.
Conclusion. This study is the first to identify
different expression patterns between 2 areas of the
synovial membrane from the same patient. These differ-
ences concern several key pathways involved in OA
pathogenesis. This analysis also provides information
regarding new genes and proteins as potential targets of
treatment.
Osteoarthritis (OA) is the most common joint
disease and is a major cause of joint pain and disability
in the aging population (1). OA is a degenerative disease
associated with an abnormal remodeling of joint tissues
principally driven by a host of inflammatory mediators
within the affected joint (2). Its etiology is multifactorial
(i.e., age, obesity, joint injury, genetic predisposition),
and the pathophysiologic process affects the entire joint
(articular cartilage, subchondral bone, synovial mem-
brane, menisci and ligaments, muscles and nerves).
Destruction of articular cartilage, sclerosis of subchon-
dral bone, and formation of osteophytes, synovial in-
flammation, and ligament and meniscal damage consti-
tute the main features characterizing OA.
Over the last decade, attention has turned to the
importance of synovial inflammation in OA. Synovial
inflammation has been proven to contribute to patient
symptoms (joint swelling and pain from inflammation),
signs (effusion), and disease progression (3). It is in-
volved early in the disease process (4) and is thought
to be secondary to osteocartilaginous fragments and
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inflammatory/catabolic factors entering the synovial cav-
ity (5). Synovial histologic changes in OA include syno-
vial hypertrophy and hyperplasia, with an increase in the
number of synovial lining cells often accompanied by
infiltration of lymphocytes and macrophages either dif-
fusely or in perivascular aggregates (3,6). The inflamma-
tion is mostly confined to areas adjacent to pathologi-
cally damaged cartilage and bone (7).
Synovial inflammation is promoted by a large
number of soluble mediators of inflammation. Among
them, interleukin-1 (IL-1) and tumor necrosis factor
 (TNF) are the 2 major cytokines involved in the
pathogenesis of OA (6). In addition to inducing the
synthesis of matrix metalloproteinases (MMPs) and
other proteinases, IL-1 and TNF can not only induce
their own production but also stimulate chondrocytes,
synovial cells, and T lymphocytes to produce other
cytokines (i.e., IL-6, IL-8, IL-15, IL-17, leukemia inhib-
itory factor) and prostaglandin E2 (2,8). In patients at
an early stage of OA, the expression of synovial chemo-
kines was found to be associated with the presence of
synovial inflammation (9), and the expression of CCL19
and its receptor CCR7 was associated with most severe
symptoms.
Finally, recent studies have implicated alarmins
in synovial inflammation. The alarmins S100A8 and
S100A9 are crucially involved in synovial activation and
cartilage destruction during OA, and their elevated
levels may predict joint destruction (10).
Synovial neovascularization is another important
feature of the inflamed synovial membrane, resulting
from an imbalance between pro- and antiangiogenic
factors (11). The neovascularization may be largely
driven by synovitis (12). Therefore, angiogenesis and
inflammation are 2 key closely integrated and interre-
lated processes that may affect disease progression and
pain (13).
Our research group has developed an original
methodology to investigate the cross-talk between an-
giogenesis and inflammation, comparing different areas
of the synovial membrane with various levels of severity
of synovitis (14). This method consists of selecting
samples from normal/reactive or inflamed areas from
the same OA patient using the Ayral synovitis score, in
order to culture cells from these areas separately (15).
This model led us to observe and compare concomitant
pathophysiologic pathways. Our first results showed that
synovial cells from an inflamed area produced more
proinflammatory cytokines (IL-6 and IL-8), more vascu-
lar endothelial growth factor (VEGF), and less throm-
bospondin 1 (TSP-1) than synovial cells from a normal/
reactive area, suggesting an imbalance between pro- and
antiangiogenic factors in favor of proangiogenic factors
(14). In addition, VEGF production showed a strong
positive correlation with IL-6 and IL-8 secretion, while a
significant negative correlation was obtained between
TSP-1 and IL-8. This last observation indicates the link
that exists between inflammation and angiogenesis in
the synovial membrane (14).
Transcriptomic analysis is of growing importance
in understanding how altered gene expression contrib-
utes to complex disease, providing greater insights into
biologic pathways and molecular mechanisms that reg-
ulate disease development and progression. In the pres-
ent study, we compared gene expression profiles of
synovial cells isolated from inflamed or normal/reactive
areas of synovial membrane from OA patients. We
identified key pathways involved in OA pathogenesis
and, subsequently, new potential targets for OA treat-
ment.
PATIENTS AND METHODS
Patients. Synovial tissue samples from 12 patients with
knee OA (10 women and 2 men; mean age 70 years, range
50–83 years) were obtained at the time of total knee joint
replacement surgery. All subjects provided informed consent,
and ethical approval (ethics committee agreement of Catholic
University of Louvain, no. B403201111664) was granted for
this study. The inflammation status of the synovial membrane
was characterized by the surgeon according to macroscopic
criteria established by Ayral (15). These criteria included
synovial vascularization, villi formation, and hypertrophic as-
pect of the tissue and allowed the classification of the synovial
membrane into 3 grades: normal, reactive, and inflamed. For
the purposes of this study, synovial samples were grouped as
normal/reactive or inflamed.
Isolation and culture of synovial cells. Normal/reactive
and inflamed synovial biopsy samples were separately digested
as previously described (14) with type IA collagenase from
Clostridium histolyticum (1 mg/ml; Sigma-Aldrich) in complete
medium, consisting of Dulbecco’s modified Eagle’s medium
(Lonza) supplemented with 10 mM HEPES, 100 units/ml
penicillin, 100 g/ml streptomycin, 2 mM L-glutamine, and
10% fetal calf serum (Lonza), for 4 hours at 37°C. The cell
suspensions were passed through a 70-m filter to remove any
undigested tissue. The filtered cell suspensions were then
collected by centrifugation at 800g. Synovial cells from either
normal/reactive or inflamed biopsy samples were cultured
separately in a T25 cell culture flask in 10 ml of complete
medium, at 37°C in a 5% CO2 humidified atmosphere. After
2 days, medium was changed to remove nonadherent cells, and
cells were cultured in fresh medium for 5 days. At the end of
these 5 days of culture, culture media and cells were collected
for further analysis.
RNA extraction. Total RNA was extracted using an
RNeasy Mini Kit (Qiagen) and reverse-transcribed with
SuperScript III reverse transcriptase according to the instruc-
tions of the manufacturer (Invitrogen). The yield of the
extracted RNA was determined spectrophotometrically by
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measuring the optical density at 260 nm. The purity and
quality of extracted RNA were evaluated using an Experion
RNA StdSens Analysis Kit (Bio-Rad). High-quality RNA with
RNA quality indicator scores of 8 was used for microarray
experiments.
Microarray. Gene expression profiling was performed
using an Illumina multisample format Human HT-12 v4 Bead-
Chip, which contains more than 47,000 probes and which
profiles 12 samples simultaneously on a single chip. For each
sample, 250 ng of total RNA was labeled using an Illumina
TotalPrep-96 RNA Amplification Kit (Ambion) according to
the manufacturer’s instructions. Briefly, double-stranded com-
plementary DNA was synthesized using T7-oligo(dT) primers,
followed by an in vitro transcription reaction to amplify
antisense RNA while biotin was incorporated into the synthe-
sized antisense RNA probe. The antisense RNA probe was
then purified and quantified using a NanoDrop spectrophoto-
meter (Thermo Fisher Scientific). The biotinylated comple-
mentary RNA probe was hybridized to the Human HT-12 v4
BeadChip. Labeled antisense RNA (750 ng) was used for
hybridization to each array. The hybridization, washing, and
scanning were performed according to the manufacturer’s
instructions. The arrays were scanned using a BeadArray
Reader (Illumina). The microarray images were registered
and extracted automatically during the scan according to the
manufacturer’s default settings. Raw microarray intensity data
were analyzed with GenomeStudio software and normalized
using the quantile normalization method according to the
manufacturer’s recommendation.
Differential analysis was performed with Biometric
Research Branch (BRB) ArrayTools software (available at
http://linus.nci.nih.gov/BRB-ArrayTools.html). The quantile-
normalized data were loaded as a single file in BRB Array-
Tools. They are filtered out based on the variance for the gene
across the arrays, a feature included in BRB ArrayTools that
allows the removal of unexpressed or equally expressed tran-
scripts. The variance of the log ratios for each gene is
compared to the median of all the variances. Those genes not
significantly more variable than the median gene are filtered
out. Specifically, the quantity (n – 1) Vari/Varmed is computed
for each gene i. Vari is the variance of the log intensity for gene
i across the entire set of n arrays, and Varmed is the median of
these gene-specific variances. This quantity is compared to a
percentile of the chi-square distribution with n – 1 degrees of
freedom. This is an approximate test of the hypothesis that
gene i has the same variance as the median variance. We used
the threshold of P  0.05 for the chi-square test. Of 47,231
probes used on the array, 17,511 passed the filter.
The Class Comparison Tool (BRB ArrayTools) com-
putes the number of genes that are differentially expressed
among the classes at the statistical significance level selected in
the t-test menu and creates a gene list containing information
about the significant genes. The Class Comparison between
Groups of Arrays Tool computes a t-test separately for each
gene using the normalized log intensities for 1-color oligo-
nucleotide arrays. Since the normal/reactive and inflamed
samples came from the same patient, we use the option
“paired t-test,” available in BRB ArrayTools, to improve the
statistical power of the analysis. The Class Comparison Tool
also provides univariate permutation tests for the significance
of individual genes. The univariate permutation tests are
computed separately for each gene. The output gene list table
is ordered by univariate P value with the most significant genes
listed first. The false discovery rate (FDR), computed by the
Benjamini and Hochberg method, associated with a row of the
table is an estimate of the proportion of the genes that
represent false-positives and that have univariate P values less
than or equal to the P value in that row. We used a paired t-test
P value threshold of less than 0.005 in our analysis; we
computed an FDR of 0.0975 for the last statistically selected
probe.
All data have been deposited in NCBI GEO (16) and
are accessible through GEO Series accession no. GSE46750
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?accGSE46750).
The biologic relevance of up- and down-regulated genes was
analyzed using IPA (Ingenuity Systems).
Western blotting. Cells were collected at 4°C and lysed
for 30 minutes on ice in 100 l of buffer (25 mM HEPES,
150 mM NaCl, 0.5% Triton X-100, 10% glycerol, and 1 mM
dithiothreitol) containing phosphatase inhibitors (1 mM
Na3VO4, 25 mM -glycerophosphate, and 1 mM NaF). Total
protein extracts (20 g; independent protein extracts from
3 different patients) were fractionated by electrophoresis on
a polyacrylamide gel (15% for S100A9; 10% for stanniocalcin
1 [STC1], triggering receptor expressed on myeloid cells
1 [TREM-1], -tubulin, and Wnt-5a) and transferred onto an
Immobilon-P membrane (PVDF; Millipore). Membranes were
blocked in 1% blocking solution (Western blocking reagent;
Roche) overnight at 4°C without shaking. Membranes were
then incubated for 2 hours with primary antibodies (against
S100A9, Wnt-5a, STC1, TREM-1, and -tubulin) diluted in
0.5% blocking solution. Mouse monoclonal anti-S100A9
(sc-376772; 1:2,000 dilution), anti–Wnt-5a (sc-365370; 1:100
dilution), and anti–-tubulin (sc-8035; 1:1,000 dilution) anti-
bodies as well as goat polyclonal anti-STC1 (sc-14346; 1:250
dilution) and anti–TREM-1 (sc-19310; 1:100 dilution) antibod-
ies were purchased from Santa Cruz Biotechnology. Horse-
radish peroxidase (HRP)–linked anti-goat or anti-mouse IgG
antibodies (Dako) were used as secondary antibodies. The
reaction was revealed with enhanced chemiluminescence de-
tection reagent according to the manufacturer’s instructions
(ECL kit; Amersham Pharmacia Biotech). THP-1 cell lysate
(sc-2238), HL-60 whole cell lysate (sc-2209), and 293T lysate
(sc-124651) were used as positive controls for anti–TREM-1,
anti-S100A9, and anti–Wnt-5a antibodies, respectively (data
not shown).
Immunohistochemistry. Synovial biopsy samples from
normal/reactive or inflamed areas were fixed, dehydrated in
xylene, and embedded in paraffin using standard procedures.
Five-micrometer sections were cut and deparaffinized accord-
ing to standard protocol. These sections were stained with
anti-STC1 (1:50 dilution), anti-S100A9 (1:100 dilution), and
anti–hyaluronan synthase 1 (anti–HAS-1) (sc-23145; 1:50 dilu-
tion) antibodies. Antibodies were purchased from Santa Cruz
Biotechnology. Secondary antibodies, HRP enzyme conjugate,
and 3,3-diaminobenzidine substrate were used to develop
immunostaining in accordance with the instructions of the
manufacturer (Dako). Slides were counterstained with hema-
toxylin and eosin. Negative control experiments were per-
formed with isotype controls for IgG: normal goat IgG for
STC1 and HAS-1 (AB-108-C; 1:250 dilution) (R&D Systems)
and mouse IgG1 for S100A9 (X0931; 1:50 dilution); (Dako).
962 LAMBERT ET AL
RESULTS
Global microarray results. From among 47,000
probes, 17,500 were filtered out. Differential analysis
was done from these 17,500 filtered probes. The Class
Comparison test between normal/reactive and inflamed
areas was based on a paired t-test where normal/reactive
and inflamed areas were paired for each patient (n 
12). Probes with a P value less than 0.005 were chosen
as up- or down-regulated ones. The 896 genes identified
as differentially expressed between normal/reactive and
inflamed areas are listed in Supplementary Table 1,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38315/
abstract.
Main pathways identified. Based on the standard
networks generated by IPA, the analysis was deepened
in order to identify specific OA pathways. A significant
number of genes that were differentially expressed be-
tween normal/reactive and inflamed OA synovial biopsy
samples were categorized as belonging to inflammation,
cartilage extracellular matrix metabolism, Wnt signaling,
and angiogenesis pathways. Inflamed synovium:normal/
reactive synovium ratios of 1.5 and 0.75 were con-
sidered relevant. The 4 key pathways were analyzed in
detail.
Inflammation network. As presented in Table 1, a
large number of mediators of inflammation were dem-
onstrated to be up-regulated in inflamed compared with
normal/reactive OA synovial biopsy samples. These me-
diators belonged to different categories: inflammatory
cytokines, chemokines, enzymes, and their related part-
ners. In addition, this allowed the identification of
2 genes of interest in the inflammation process: TREM1
(P  0.0003929, FDR 0.0783) and the alarmin S100A9
(P  0.0014609, FDR 0.083).
To validate the differential expression of
TREM1 in OA synovial biopsy samples, we performed
Western blot analyses. As illustrated in Figure 1, the
level of TREM-1 protein was increased in inflamed
compared with normal/reactive areas. Similarly, S100A9
was evaluated and an increase of protein production was
observed in inflamed compared with normal/reactive
areas (Figure 1). These results were confirmed by im-
munohistochemistry (Figures 2A–D). In inflamed
synovial biopsy samples, staining for S100A9 was ob-
served in perivascular and sublining cells. Increased
staining was observed in the intima lining layer of
inflamed biopsy samples compared with normal/reactive
biopsy samples.
Cartilage metabolism pathway. The comparison
between normal/reactive and inflamed synovial biopsy
samples highlighted several factors involved in both
cartilage anabolism and catabolism (Table 1). Interest-
ingly, the differential expression of these genes revealed
an imbalance between anabolism and catabolism. Thus,
MMP3 (P  0.0044072, FDR 0.0955), MMP9 (P 
0.0013676, FDR 0.0824), CTSH (cathepsin H) (P 
0.0032275, FDR  0.0931), and CTSS (cathepsin S)
Table 1. Genes differentially expressed between normal/reactive and inflamed areas of synovial biopsy samples*
Pathway, type
of compound Up-regulated Down-regulated
Inflammation
Cytokines IL8 (4.45), IL6 (3.43), TNFRSF21 (1.99), IFI30 (1.91),
TNFAIP6 (1.62), IRF8 (1.61)
–
Chemokines CXCL5 (4.38), CXCL6 (3.89), CXCL16 (2.8), CXCL2 (2.62),
CXCL1 (2.52)
–
Enzymes ALOX5AP (3.35), PLD1 (2.64), ALOX5 (2.32),
PTGES (2.04), PLCB1 (1.87), SOD2 (1.79),
TBXAS1 (1.75), PI3 (1.71), PLA2G4A (1.58)
–
Other TREM1 (3.45), S100A9 (2.68), OSM (1.57), PPARG (1.49) –
Anabolism HAS1 (2.16), BMP6 (2.48), COLL22A1 (2.05) COL1A2 (0.75), VIM (0.75), MATN2 (0.74),
HABP4 (0.72), HAPLN1 (0.66), HAS3 (0.65),
COL16A1 (0.64), CILP (0.63), COL6A3 (0.63),
GPC4 (0.58), HAPLN1 (0.58), ACAN (0.42)
Catabolism MMP9 (3.53), MMP3 (2.82), CTSH (2.02), ADAMDEC1 (1.76),
CTSS (1.52)
–
Angiogenesis STC1 (5.83), PF4V1 (2.97), EDNRB (2.64), AQP9 (2.58),
HBEGF (2.51), BDKRB1 (2.4), RCAN1 (2.31), ECGF1 (1.97),
DNER (1.85), RCAN1 (1.84), BDKRB2 (1.7), PECAM1 (1.65)
PDGFC (0.71), RNH1 (0.69)
* Values in parentheses correspond to fold change of expression between normal/reactive and inflamed areas. Genes represented more than once
(HAPLN1 and RCAN1) reflect different splice variants or transcript variants.
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(P  0.0015613, FDR 0.0837) were significantly up-
regulated in inflamed synovial biopsy samples. In con-
trast, the most highly up-regulated anabolism enzyme
gene was HAS1 (P  0.0006656, FDR 0.0809). This
observation was confirmed at the protein level using
immunohistochemistry. In inflamed synovial biopsy sam-
ples, there was an increase in HAS-1–positive cells with
predominant localization in the intima lining (Figures
3A–D).
Wnt signaling pathway. As revealed by the net-
work analysis, the Wnt signaling pathway was differen-
tially activated between normal/reactive and inflamed
OA synovial biopsy samples. Indeed, genes for Wnt-5a
(P  0.0030684, FDR 0.0931) and low-density lipopro-
Figure 1. Increase of triggering receptor expressed on myeloid cells 1 (TREM-1), S100A9, stanniocalcin 1 (STC1), and Wnt-5a protein production
in inflamed (I) areas compared with normal/reactive (N/R) areas. Total protein extracts from normal/reactive or inflamed areas were analyzed by
Western blotting with anti–TREM-1 (30/26 kd), anti-S100A9 (14 kd), anti-STC1 (31 kd), anti–Wnt-5a (42 kd), and anti–-tubulin (55 kd; control)
antibodies. Representative images are shown (independent protein extracts from 3 different patients).
Figure 2. Immunohistochemical detection of S100A9 in normal/reactive (A and C) and inflamed (B and D) synovial biopsy samples. Also shown
are negative controls with mouse IgG1 in normal/reactive (E) and inflamed (F) synovial biopsy samples. In inflamed synovial biopsy samples, staining
for S100A9 is observed in perivascular and sublining cells. At the time of surgery, synovial biopsy samples from normal/reactive or inflamed areas
were macroscopically selected as described in Patients and Methods. Normal/reactive and inflamed synovial biopsy samples were stained with
anti-S100A9 antibody. Representative images are shown. Arrows indicate intima lining; asterisks indicate blood vessels. Original magnification 
5 in A and B;  10 in C–F.
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tein receptor–related protein 5 (P  0.0023973, FDR
0.0881) were significantly up-regulated (2.11-fold and
1.55-fold, respectively). In contrast, the gene Frizzled
family receptor 2 (FZD2) (P  0.0036821, FDR 0.0931)
and the genes for Dkk-3 (P  0.0049476, FDR 0.0974)
and Wnt-5b (P  0.0014003, FDR 0.083) were signifi-
cantly down-regulated (0.76-fold, 0.69-fold, and 0.57-
fold, respectively).
To confirm the implications of the Wnt signaling
pathway in synovial inflammation at the protein level,
we studied the production of Wnt-5a, the most highly
up-regulated gene of this pathway. As shown in Figure 1,
the level of Wnt-5a protein was increased in the in-
flamed area compared with the normal/reactive area of
the OA synovial membrane.
Angiogenesis pathway. The other identified and
relevant pathway for OA was angiogenesis. Many genes
in this pathway were significantly up- or down-regulated
Figure 3. Immunohistochemical detection of hyaluronan synthase 1 (HAS-1) in normal/reactive (A and C) and inflamed (B and D) synovial biopsy
samples. Also shown are negative controls with normal goat IgG in normal/reactive (E) and inflamed (F) synovial biopsy samples. In inflamed
synovial biopsy samples, there is an increase in HAS-1–positive cells with predominant localization in the intima lining. At the time of surgery,
synovial biopsy samples from normal/reactive or inflamed areas were macroscopically selected as described in Patients and Methods. Normal/
reactive and inflamed synovial biopsy samples were stained with anti–HAS-1 antibody. Representative images are shown. Arrows indicate intima
lining. Original magnification  5 in A and B;  10 in C–F.
Figure 4. Immunohistochemical detection of stanniocalcin 1 (STC1) in normal/reactive (A and C) and inflamed (B and D) synovial biopsy samples.
Also shown are negative controls with normal goat IgG in normal/reactive (E) and inflamed (F) synovial biopsy samples. In inflamed synovial biopsy
samples, staining for STC1 is observed in perivascular and sublining cells. At the time of surgery, synovial biopsy samples from normal/reactive or
inflamed areas were macroscopically selected as described in Patients and Methods. Normal/reactive and inflamed synovial biopsy samples were
stained with anti-STC1 antibody. Representative images are shown. Arrows indicate intima lining; asterisks indicate blood vessels. Original
magnification  5 in A and B;  10 in C–F.
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(Table 1). Interesting mediators such as aquaporin 9
(AQP9) (P  0.0003422, FDR 0.0783) and delta/notch-
like epidermal growth factor repeat containing (DNER)
(P  0.0019947, FDR 0.0876) were shown to be signif-
icantly increased.
Among these genes, one of the most highly
up-regulated was STC1 (5.83-fold increased expression;
P 0.0008499, FDR 0.0809). Consistent with the microar-
ray data, a significant increase of STC1 production was
observed in inflamed compared with normal/reactive areas
byWestern blot analysis (Figure 1). These results were also
supported by immunohistochemical analysis. Indeed, in the
inflamed area (Figures 4B and D), the staining for STC1 in
perivascular and sublining cells was more intense than in
the normal/reactive area (Figures 4A and C).
DISCUSSION
Transcriptome analysis represents a promising
approach in the understanding of complex diseases such
as OA. In past years, reports of several studies aiming
to determine the involvement of gene modulation have
been published. These studies focused on human knee
and hip cartilage as well as on cultured fibroblasts from
knee synovial tissues (17).
The main conceptual questions raised by re-
searchers are how samples from different patients can
be pooled together and how the observed level of gene
expression should be compared with that in appropriate
controls. It is indeed obvious that a wide clinical hetero-
geneity can be found among patients due to both
individual factors and disease characteristics. The com-
parison of the observed gene expression level with that
in an appropriate control group or “healthy subject
group” is also subject to debate. Samples considered
healthy are commonly obtained from knee joints at
necropsy or during arthroscopic examination, from me-
niscal lesions or from joints appearing normal on mag-
netic resonance imaging (18). Consequently, depending
on the nature of the sample, an important heterogeneity
among controls can also be observed.
The principal originality and novelty of the pres-
ent work was to compare, using microarray analysis, the
gene expression pattern of synovial cells from inflamed
and normal/reactive areas of synovial membrane from
the same OA patient. Methodologically, we used a
rigorous procedure including macroscopic and histologic
evaluation (15), flow cytometry analysis, and measure-
ment of proinflammatory mediators to confirm the
accuracy and reliability of our sampling method. Sam-
ples were digested and cultured for 7 days to enable us
to use cells at passage 0 for our microarray experiments.
In these cultures, flow cytometry analysis demonstrated
the lack of contamination with other cell types, espe-
cially lymphocytes and endothelial cells that might have
interfered with the microarray analysis (normal/reactive
area 90.3% CD90, 1.4% CD14, and 0.8% CD3;
inflamed area 92.6% CD90, 1.7% CD14, and 1.3%
CD3). We also demonstrated that, in our model, the
inflammatory profile of synoviocytes from the inflamed
area was conserved, since we measured higher levels of
IL-6 and IL-8 in culture medium (14).
Our microarray analysis showed that numerous
genes involved in the inflammation, cartilage anabolism/
catabolism, and angiogenesis pathways are differentially
expressed in synovial membrane biopsy samples from
inflamed and normal/reactive areas. Regarding the in-
flammation pathway, we confirmed the up-regulation of
a large number of cytokine and chemokine genes, such
as IL6, IL8, CXCL5, CXCL6, CXCL16, CXCL2, and
CXCL1. In addition, we confirmed the up-regulation of
genes for 2 interesting proteins, TREM-1 and S100A9.
Since the discovery of TREM-1, much evidence has
suggested that it has an important ability to regulate
inflammation (19). TREM-1 is a recently identified
immunoglobulin-like cell surface receptor with no cyto-
plasmic signaling domain (20). Its natural ligand is
unknown, but its activation leads to the production of
multiple proinflammatory cytokines and chemokines.
This response can in turn amplify inflammatory re-
sponses (21). Our data indicated that TREM-1 expres-
sion is increased in inflamed compared with normal/
reactive areas of OA synovial membrane, suggesting a
potential role of this glycoprotein in OA synovitis.
Further, TREM-1 was absent from normal/reactive syno-
vial cell extracts, indicating a focal expression of this
factor in inflamed areas of OA synovial membrane.
TREM-1 appears to be an interesting therapeutic target
and could be a marker of OA synovitis.
S100A9 is a member of the alarmin family (22).
This alarmin is a pivotal protein in synovial inflamma-
tion and cartilage destruction in OA (10). In cartilage,
S100A9 expression is restricted to hypertrophic chon-
drocytes and plays a major role in the mineralization of
the cartilage matrix (23). High levels of S100A9 have
been found in synovial fluid from OA patients and
patients with rheumatoid arthritis (RA) (10-fold higher
levels in synovial fluid from RA patients compared with
OA patients) (24). The analysis of arthroscopic synovial
biopsy samples from patients with early symptomatic
OA in the Cohort Hip and Cohort Knee study also
revealed increased levels of S100A9 (messenger RNA
[mRNA] and protein), which correlated significantly
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with synovial lining thickness, cellularity in the subin-
tima, and joint destruction (10).
An imbalance between anabolic and catabolic
genes in favor of catabolic genes was also demonstrated.
Indeed, the magnitude of fold expression was higher for
catabolic genes. This disequilibrium is observed in car-
tilage during OA. In addition, it has been suggested that
synovitis may accelerate the catabolism of articular
cartilage and contribute to the progression of chondro-
pathy by the production of a large amount of MMPs
(25). Indeed, our results indicated that the genes MMP3
and MMP9 were up-regulated in inflamed compared
with normal/reactive areas. Several results reported in
the literature are concordant with our results. Yuan et al
(25) observed a preferential localization of MMP-3 in
pannus-like tissue covering hyaline cartilage, suggesting
that this mediator was secreted by OA synovial tissue
and acted directly to degrade cartilage. We also showed
an up-regulation of bone morphogenetic protein 6
(BMP-6). This protein is classically implicated in carti-
lage and bone repair in arthritis. However, Lories et al
also demonstrated that BMP-6 was expressed in arthritic
synovium and strongly up-regulated by proinflammatory
cytokines (26).
We previously demonstrated the importance of
angiogenesis in synovitis as well as the close link between
angiogenesis and inflammation (14). These results are
supported by the data generated in the present micro-
array analysis. We showed that various key mediators of
angiogenesis were differently expressed in inflamed and
normal/reactive synovial membrane. For example, we
observed an up-regulation of the gene for AQP-9. The
aquaporins are involved in cell migration and angiogen-
esis (27). Moreover, Nagahara et al (28) reported that
AQP-9 mRNA was detected in synovial tissues from OA
and RA patients with hydrarthrosis and that its expres-
sion was strongly induced in fibroblast-like synoviocytes
by TNF, suggesting that AQP-9 might be related to
synovitis.
Besides these confirmatory results, our study has
identified several potential targets of interest for the
treatment of OA. We demonstrated for the first time the
up-regulation, at both the gene and protein levels, of
STC1, a glycoprotein hormone originally discovered in
the corpuscles of Stannius of bony fish (29). Recent work
has indicated that STC1 may be involved in the control
of the angiogenesis process (30). STC1 is described as a
vascular-specific angiogenesis-associated protein. It
plays roles in “angiogenic sprouting” via the VEGF/
VEGF receptor 2 pathway (31). These observations
suggest that STC1 could be a key mediator of synovium
neovascularization in OA synovitis.
In our microarray analysis, the Wnt signaling
pathway was differentially activated in inflamed com-
pared with normal/reactive OA synovial biopsy samples.
More particularly, we found an up-regulation of Wnt-5a,
a ligand that activates the -catenin–independent path-
way. Wnt-5a was involved in IL-1–induced MMP ex-
pression and chondrocyte differentiation, suggesting
that it might be involved in cartilage destruction (32). A
better understanding of Wnt signaling and the members
of this pathway could be an approach to therapeutic
management of OA.
Additionally, we noted a series of genes that were
differently regulated in inflamed compared with normal/
reactive areas of OA synovial membrane, but have not to
date been associated with OA pathogenesis. These
include up-regulated genes such as hydroxysteroid (11-
beta) dehydrogenase 1 (HSD11B1), the solute carrier
organic anion transporter (SLCO) family, or microRNA
(MIR1275, 199A2, 221, and 302c) and down-regulated
genes such as cysteine-rich protein 2 (CRIP2), lysyl
oxidase–like 1 (LOXL1), or AHNAK nucleoprotein. A
better understanding of the role played by these genes in
OA pathogenesis could lead to the identification of new
therapeutic targets.
In conclusion, our microarray analysis has re-
vealed genes that were focally regulated in OA synovial
membrane. These genes are associated with important
pathophysiologic processes in OA and represent candi-
date targets for OA treatment. Using a unique culture
system, this study is the first to identify different expres-
sion patterns between 2 areas of the synovial membrane
from the same patient. As expected, these differences
concern key pathways involved in OA pathogenesis. This
analysis also provided novel information regarding new
genes of interest (STC1, S100A9) and provided evidence
of the involvement of the Wnt-5a signaling pathway in
OA.
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